Intersect ENT Inc (NASDAQ:XENT) insider Lisa D. Earnhardt sold 10,685 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $31.87, for a total transaction of $340,530.95. Following the sale, the insider now directly owns 487,868 shares in the company, valued at approximately $15,548,353.16. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Intersect ENT Inc (NASDAQ XENT) opened at $32.00 on Tuesday. Intersect ENT Inc has a fifty-two week low of $11.15 and a fifty-two week high of $34.40.
Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The business had revenue of $22.31 million for the quarter, compared to analyst estimates of $21.53 million. During the same quarter in the previous year, the firm earned ($0.22) EPS. The company’s quarterly revenue was up 20.8% compared to the same quarter last year. research analysts anticipate that Intersect ENT Inc will post -0.63 EPS for the current year.
A number of equities research analysts recently issued reports on the stock. Northland Securities reissued a “hold” rating and issued a $25.00 price target on shares of Intersect ENT in a research note on Friday, November 3rd. Piper Jaffray Companies restated a “buy” rating and issued a $35.00 price objective on shares of Intersect ENT in a report on Tuesday, August 22nd. Zacks Investment Research upgraded Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a report on Thursday, October 5th. BidaskClub lowered Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Finally, BTIG Research restated a “hold” rating on shares of Intersect ENT in a report on Tuesday, November 7th. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $33.38.
TRADEMARK VIOLATION NOTICE: This story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/12/19/intersect-ent-inc-xent-insider-lisa-d-earnhardt-sells-10685-shares.html.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
What are top analysts saying about Intersect ENT? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intersect ENT and related companies.